The detection rate of PET/CT with 18F-PSMA-targeted agents was influenced by serum PSA with lower values in PCa patients with PSA < 0.5 ng/mL (49%) compared to those with PSA ≥ 0.5 ng/mL (86%). This evidence concerns the gene KLK3 and posterior cortical atrophy.